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Abstract
Objective:	To	estimate	the	effect	of	locally	tailored	clinical	guidelines	on	intrapartum	
care	 and	 perinatal	 outcomes	 among	women	with	 severe	 hypertensive	 disorders	 in	
pregnancy	(sHDP).
Methods:	A	pre–post	 study	 at	Zanzibar’s	 low-	resource	Mnazi	Mmoja	Hospital	was	
conducted.	All	labouring	women	with	sHDP	were	included	at	baseline	(October	2014	
to	January	2015)	and	at	9–12	months	after	implementation	of	the	ongoing	interven-
tion	(October	2015	to	January	2016).	Background	characteristics,	clinical	practice,	and	
delivery	outcomes	were	assessed	by	criterion-	based	case	file	reviews.
Results:	Overall,	188	of	2761	(6.8%)	women	had	sHDP	at	baseline,	and	196	of	2398	
(8.2%)	did	so	during	 the	 intervention	months.	The	median	time	between	 last	blood	
pressure	 recording	 and	 delivery	 decreased	 during	 the	 intervention	 compared	 with	
baseline	(P=0.015).	Among	women	with	severe	hypertension,	antihypertensive	treat-
ment	 increased	 during	 the	 intervention	 compared	 with	 baseline	 (relative	 risk	 [RR]	
1.37,	95%	confidence	interval	[CI]	1.14–1.66).	Among	the	neonates	delivered	(birth-
weight	≥1000	g),	stillbirths	decreased	(RR	0.56,	95%	CI	0.35–0.90)	and	Apgar	scores	
of	seven	or	more	increased	during	the	intervention	compared	with	baseline	(RR	1.17,	
95%	CI	1.03–1.33).
Conclusion:	 Although	 health	 system	 strengthening	 remains	 crucial,	 locally	 tailored	
clinical	guidelines	seemed	to	help	work-	overloaded	birth	attendants	at	a	low-	resource	
hospital	to	improve	care	for	women	with	sHDP.
ClinicalTrials.org:	NCT02318420.
K E Y W O R D S
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1  | INTRODUCTION
Hypertensive	disorders	in	pregnancy	(HDP)	cause	one-	tenth	of	mater-
nal	 deaths	 in	 Africa.1,2	 A	 previous	 facility-	based	 survey	 in	 low-	 and	
middle-	income	countries	found	that	the	 likelihood	of	maternal	near-	
miss	was	eightfold	and	perinatal	death	threefold	higher	in	a	group	of	
women	with	pre-	eclampsia	than	in	a	reference	group	without	HDP.2 
Although	most	 cases	 are	 preventable,	 undiagnosed	 or	 suboptimally	
treated	 HDP	 is	 repeatedly	 reported	 in	 sub-	Saharan	 Africa.3–10	 This	
violates	human	rights	and	is	a	key	priority	for	safe	motherhood.11,12
Hypertensive	disorders	in	pregnancy	can	rapidly	progress	in	sever-
ity,	with	increased	risk	of	organ	failure	such	as	cerebral	hemorrhage,	
coagulopathy,	eclampsia,	and	pulmonary	edema.	Lifesaving	treatment	
includes	 induction	and/or	oxytocin	augmentation	of	 labor	while	sta-
bilizing	blood	pressure	(BP)	and	supporting	vital	organ	functions.13,14 
In	high-	volume	low-	resource	hospitals,	urgent	intrapartum	diagnosis,	
surveillance,	and	management	of	such	complex	diseases	are	challeng-
ing	and	need	realistic	practical	guidance.3,5–9,15,16
In	 Tanzania,	 however,	 only	 one-	third	 of	 maternity	 units	 have	
emergency	obstetric	 care	guidelines	 available,	 and	only	one-	quarter	
have	at	 least	one	birth	attendant	with	adequate	training	 in	applying	
these.17	 Even	 if	 available,	 guidelines	 are	 often	 not	 tailored	 to	 low-	
resource	 settings.9,15,16,18	Unachievable	 international	guidelines	 limit	
implementation	and	may	demoralize	staff.	Clinical	guidelines	tailored	
and	disseminated	to	facilitate	effective	application	in	low-	resource	set-
tings	are	required.15,17,18
Zanzibar	 is	 a	 low-	income,	 semiautonomous	 archipelago	 of	 the	
United	Republic	 of	Tanzania,	with	 a	 facility	 delivery	 rate	 of	 55%.	 In	
its	 tertiary	Mnazi	Mmoja	Hospital,	 approximately	 12	000	 births	 are	
attended	 to	 annually.	 There	 were	 59	 stillbirths	 per	 1000	 births	 in	
2014–2015,	and	52	neonates	per	1000	live	births	had	an	Apgar	score	
of	1–5.	Approximately	half	of	the	stillborn	fetuses	were	alive	on	admis-
sion,	 and	 the	quality	of	 intrapartum	care	was	widely	unacceptable.3 
This	 prompted,	 in	 collaboration	 with	 doctors	 and	 nurse-	midwives,	
the	development	of	locally	achievable	clinical	guidelines	for	common	
intrapartum	 care.	 The	 resulting	 eight-	page	 PartoMa	 pocket	 book-
let	 has	 subsequently	 been	 implemented	 among	 doctors	 and	 nurse-	
midwives	by	quarterly	seminars.18	In	particular,	doctors	have	reported	
finding	 the	 booklet’s	 page	on	 essential	 intrapartum	management	 of	
HDP	useful.18	The	aim	of	the	present	study	was	therefore	to	estimate	
the	effects	of	the	PartoMa	intervention	of	pocket	guides	and	quarterly	
low-	dose	training	on	care	and	delivery	outcomes	among	women	with	
severe	HDP	(sHDP).
2  | MATERIALS AND METHODS
In	 a	 retrospective	 pre–post	 study,	 case	 files	 were	 reviewed	 for	 all	
women	with	sHDP	(defined	as	systolic	BP	160	mm	Hg	or	higher	and/
or	diastolic	BP	110	mm	Hg	or	higher	and/or	eclampsia	pre-	delivery)	
who	attended	Mnazi	Mmoja	Hospital	before	 the	PartoMa	 interven-
tion	(October	1,	2014,	to	January	31,	2015)	and	9–12	months	after	
implementation	(October	1,	2015,	to	January	31,	2016).	The	PartoMa	
study	was	approved	by	Mnazi	Mmoja	Hospital	and	Zanzibar	Medical	
and	 Research	 Ethical	 Committee	 (ZAMREC/0001/JUNE/014),	 and	
registered	with	 ClinicalTrials.org	 (NCT02318420).	 Patient	 identities	
were	anonymized,	and	thus	informed	consent	not	required.
Throughout	 the	 study,	 each	 birth	 attendant	 (nurse-	midwife	 or	
doctor)	simultaneously	cared	for	an	average	of	3–6	laboring	women,	
and	 30%	were	 intern	 doctors	 conducting	 their	 initial	 6-	week	 rota-
tion.	Turnover	was	high	among	staff	in	permanent	positions:	25%	of	
nurse-	midwives	and	40%	of	doctors	during	the	initial	6	months	of	the	
intervention	were	no	longer	working	there	after	1	year.19	As	a	result,	
most	staff	had	limited	experience	with	childbirth	care.	Only	two	had	
a	master	in	midwifery	and	there	were	only	two	obstetricians.	At	base-
line,	clinical	intrapartum	guidelines	were	not	routinely	used.	The	WHO	
composite	partograph	was	recommended	for	all	deliveries.20
The	 “PartoMa	 Pocket	 Guide”	 (File	 S1)	was	 launched	 on	 January	
27–28,	2015,	at	the	first	“PartoMa	seminars”.	These	3-hour	seminars	
were	conducted	quarterly	in	order	to	establish	use	of	the	guidelines	via	
case-	based	discussions.	They	were	conducted	outside	working	hours	
and	without	‘per	diems’	or	other	allowances.	An	average	of	74%	of	doc-
tors	and	62%	of	nurse-	midwives	from	the	obstetric	division	attended	
each	of	five	seminar	rounds	during	the	first	intervention	year.	One	page	
of	the	pocket	guide	 (Fig.	1)	and	one	of	five	seminar	cases	concerned	
intrapartum	care	for	women	with	sHDP.	Detailed	descriptions	of	guide-
lines	development	and	the	seminars	are	presented	elsewhere.18,19,21
Quality	of	intrapartum	care	for	women	with	sHDP	was	delineated	
to	diagnosis,	surveillance,	and	treatment,	and	based	on	pre-	selected	
indicators	 (Fig.	S1).	 In	addition,	maternal	background	characteristics,	
maternal	mortality,	neonatal	Apgar	score,	and	stillbirth	were	recorded,	
including	the	proportion	of	stillbirths	with	fetal	heart	rate	(FHR)	pres-
ent	on	admission.	The	indicators	were	chosen	to	represent	unambig-
uous	 audit	 criteria	 for	 low-	resource	 settings	 that	 were	 sensitive	 in	
monitoring	progress	in	care	and	could	be	retrieved	from	case	files.
Structural	changes	at	the	study	site	that	might	potentially	explain	
outcome	 changes	 (or	 lack	 of	 changes)	 after	 implementation	 of	 the	
PartoMa	 intervention	were	 assessed	 quarterly	 and	 have	 been	 pre-
viously	 described.19	 In	 brief,	 staff	 numbers,	 supply	 shortages,	 and	
available	 emergency	 obstetric	 and	 neonatal	 care	 signal	 functions	
were	similar	throughout	the	baseline	and	first	 intervention	year,	but	
there	were	16%	fewer	deliveries	during	the	ninth	to	12th	intervention	
months	 compared	with	 baseline.	Daily	 clinical	meetings	were	 intro-
duced	7	months	before	baseline	and	continued	similarly	 throughout	
the	study.	No	other	formalized	in-	house	training	or	obstetric	or	early	
neonatal	 interventions	 were	 organized.	 Only	 one	 birth	 attendant	
received	formalized	training	externally.	The	department	started	con-
ducting	maternal	death	audits	in	August	2015,	but	the	audit	findings	
were	first	presented	for	staff	after	the	12th	intervention	month.19
For	the	present	study,	the	baseline	period	was	limited	to	October	
1,	2014,	to	January	31,	2015,	because	the	hospital’s	case	file	storage	
system	did	not	work	properly	before	 this	period.19	The	 intervention	
period	 studied,	October	1,	2015,	 to	January	31,	2016	 (the	ninth	 to	
12th	intervention	months),	was	previously	used	in	the	overall	evalua-
tion	of	PartoMa.19	For	the	assessment	of	sHDP,	the	calculated	sample	
size	for	the	intervention	months	was	based	on	a	two-	sided	comparison	
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F IGURE  1  Intrapartum	management	of	hypertensive	disorders	in	pregnancy:	page	7	of	the	PartoMa	Pocket	Guide	version	1.	A	full	overview	of	
the	PartoMa	guidelines	applied	is	available	in	File	S1.	Abbreviations:	BP,	blood	pressure;	CS,	cesarean;	FHR,	fetal	heart	rate.	Reproduced	from	[18].
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of	proportions.	The	proportion	of	women	with	sHDP	treated	with	anti-
hypertensives	was	 used	 as	 a	 key	 indicator	 of	 care	 and	was	86/184	
(47%)	 at	 baseline.	 Post-	implementation,	 an	 improvement	of	 at	 least	
50%	in	the	number	of	women	treated	was	expected.	Thus,	the	sam-
ple	size	of	approximately	180	women	in	each	group	resulted	in	99.9%	
power	at	a	5%	significance	level.
A	 structured	 form	 in	 Excel	 (Microsoft,	 Redmond,	WA,	 USA)	was	
used	to	collate	data,	with	statistical	analyses	performed	in	RStudio	ver-
sion	1.1.383	(RStudio,	Boston,	MA,	USA).	Background	characteristics	
were	compared	by	using	Fisher	exact	test.	Care	and	delivery	outcomes	
were	compared	by	using	relative	risk	(RR)	and	95%	confidence	intervals	
(CIs)	for	dichotomous	indicators,	and	Mann-	Whitney	test	for	time	inter-
vals.	A	P	value	of	less	than	0.05	was	considered	statistically	significant.
3  | RESULTS
According	to	the	hospital	registers,	3599	women	gave	birth	at	base-
line	and	3002	did	so	during	the	four	intervention	months	studied,	but	
case	files	of	3609	and	3067	women	were	retrieved	from	the	respec-
tive	study	periods.	Of	these,	2761	(76.5%)	and	2398	(78.2%)	women,	
respectively,	had	at	least	one	BP	measurement,	or	had	eclampsia	doc-
umented	without	a	BP	recording,	of	whom	188	(6.8%)	and	196	(8.2%)	
fulfilled	the	criteria	for	sHDP	and	were	 included	 in	the	baseline	and	
intervention	groups.	An	additional	848	(23.5%)	and	669	(21.8%)	of	the	
women	retrieved	from	the	study	periods	had	no	BP	recorded	during	
the	whole	admission	period	(RR	0.93,	95%	CI	0.85–1.01),	respectively,	
which	could	lead	to	an	underestimation	of	sHDP	(Fig.	2).
The	 background	 characteristics	 of	 women	 with	 sHDP	 were	
comparable	between	the	baseline	and	intervention	groups:	approx-
imately	 40%	 were	 nulliparous;	 75%	 had	 completed	 34	weeks	
(birthweight	≥2000	g)	of	pregnancy;	more	than	80%	had	attended	
prenatal	care	at	 least	once	and	40%	had	at	 least	four	prenatal	vis-
its.	Among	the	multiparous	women,	30%	had	previously	lost	one	or	
more	children	 (documentation	was	 inadequate	 to	distinguish	peri-
natal	deaths	from	deaths	later	in	life).	Labor	progress	on	admission	
was	similarly	comparable	between	the	two	groups:	50%	were	admit-
ted	before	active	labor	and	2%	in	the	second	stage.	Fifteen	percent	
were	 referred	 from	 lower	 level	 facilities.	 On	 admission,	 9%	were	
diagnosed	with	intrauterine	fetal	death	(Table	S1).	Among	the	188	
women	at	baseline,	184	 (97.9%)	had	severe	hypertension	 (systolic	
BP	≥160	mm	Hg	and/or	diastolic	BP	≥110	mm	Hg)	and	70	(37.2%)	
had	 a	 systolic	 BP	 of	 180	mm	Hg	 or	 higher.	 These	 proportions	
were	comparable	with	the	intervention	group:	193	(98.5%)	and	85	
(43.4%).	The	 incidence	 of	 proteinuria	 (dipstick	measurement	 ≥2+)	
was	slightly	higher	during	the	intervention	months,	which	might	be	
due	to	fewer	women	in	this	group	lacking	a	urine	test	(Table	S1).
The	 routine	 BP	 assessments	 of	 all	 laboring	 women	 did	 not	
improve	 between	 the	 two	 periods	 (RR	 0.93,	 95%	 CI	 0.85–1.01)	
(Fig.	2).	 Among	 women	 with	 sHDP,	 diagnosis	 was	 more	 frequent	
F IGURE  2 Flow	chart	showing	women	included	in	the	study.	The	inclusion	criteria	were	severe	hypertension	(systolic	blood	pressure	[BP]	
≥160	mm	Hg	and/or	diastolic	BP	≥110	mm	Hg)	and/or	eclampsia.	A	subgroup	of	women	with	severe	pre-	eclampsia/eclampsia	were	defined	as	
having	at	least	one	recording	of	severe	hypertension	and	a	proteinuria	measurement	of	at	least	2+,	and/or	eclampsia	recorded	before	or	during	
admission.	Abbreviations:	BP,	blood	pressure;	RR,	relative	risk;	CI,	confidence	interval.	aAmong	all	women	in	labor,	routine	BP	assessments	did	
not	improve	(RR	0.93,	95%	CI	0.85–1.01).
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on	admission	 in	 the	 intervention	months	 (110	 [56.1%]),	 compared	
with	the	baseline	group	(82	[43.6%])	(RR	1.29,	95%	CI	1.05–1.58).	
Among	the	women	not	diagnosed	on	admission,	only	one	had	mild-	
to-	moderate	HDP	diagnosed	prior	 to	 severe	disease.	There	was	 a	
tendency	 toward	 a	 decrease	 in	 women	 remaining	 undiagnosed	
despite	 recorded	 inclusion	 criteria	 (RR	 0.72,	 95%	 CI	 0.51–1.00)	
(Fig.	3,	Table	1).	More	women	had	proteinuria	tested	in	the	interven-
tion	group	 (177	[90.3%])	 than	 in	 the	baseline	group	 (156	[83.0%])	
(RR	1.09,	95%	CI	1.01–1.18)	(Table	S1).
Among	women	with	vaginal	delivery	and	at	least	one	recorded	BP	
pre-	delivery,	the	median	time	between	last	BP	and	delivery	was	162	min-
utes	(interquartile	range	[IQR],	80–328	minutes;	n=126)	at	baseline	ver-
sus	129	minutes	(IQR,	60–245	minutes;	n=130)	during	the	intervention	
months	(Mann-	Whitney	test,	P=0.015).	The	proportion	of	women	with	
at	 least	one	recorded	BP	post-	delivery	 improved	from	126	(67.0%)	at	
baseline	to	151	(77.0%)	during	the	intervention	months	(RR	1.15,	95%	
CI	 1.01–1.30).	Among	140	women	 at	 baseline	 and	164	during	 inter-
vention	months	with	at	 least	one	documented	FHR,	 the	median	time	
between	the	last	FHR	and	delivery	(or	identified	intrauterine	fetal	death)	
decreased	from	150	minutes	(IQR,	60–296	minutes)	to	90	minutes	(IQR	
35–180	minutes)	(Mann-	Whitney	test,	P=0.001)	(Fig.	3,	Table	1).
Among	 the	women	with	 severe	 hypertension	 (184	 at	 baseline	
and	 193	 during	 the	 intervention	 months),	 initiation	 of	 antihyper-
tensive	treatment	increased,	from	86	(46.7%)	women	at	baseline	to	
124	(64.2%)	during	the	intervention	months	(RR	1.37,	95%	CI	1.14–
1.66).	 In	both	periods,	 90%	of	women	with	 severe	pre-	eclampsia/
eclampsia	 had	 magnesium	 sulfate	 treatment	 initiated.	 Among	 the	
110	women	at	baseline	and	127	during	the	intervention	months	with	
magnesium	sulfate	initiated,	20	(18.2%)	compared	with	44	(34.6%),	
respectively,	 had	patellar	 reflexes	 and	 respiratory	 rate	 recorded	 at	
least	once	for	surveillance	of	 toxicity	 (RR	1.91,	95%	CI	1.20–3.03)	
(Fig.	3,	Table	2).	The	median	duration	of	labor	from	diagnosing	sHDP	
to	 delivery	was	 approximately	 7	hours	 in	 both	 groups	 (IQR,	 161–
790	minutes	 and	 225–745	minutes,	 respectively;	 Mann-	Whitney	
test,	P=0.356)	(Table	2).
Among	all	deliveries	(203	at	baseline	and	206	in	the	intervention	
months),	the	mode	of	delivery	was	comparable;	58	(28.6%)	were	deliv-
ered	 by	 cesarean	 at	 baseline	 compared	with	 63	 (30.6%)	 during	 the	
intervention	months.	Among	65	 (34.6%)	women	at	baseline	 and	66	
(33.7%)	during	the	intervention	months,	there	were	no	records	in	their	
medical	file	after	the	day	of	delivery;	although	it	seems	unlikely,	it	 is	
unknown	whether	these	women	had	been	discharged.
Birthweight	was	1000	g	or	more	for	201	(99.0%)	neonates	at	base-
line	and	196	(95.1%)	during	the	intervention	months.	Of	these,	the	inci-
dence	of	stillbirth	decreased	from	42	(20.9%)	at	baseline	to	23	(11.7%)	
during	intervention	months	(RR	0.56,	95%	CI	0.35–0.90),	and	the	inci-
dence	of	an	Apgar	score	of	seven	or	higher	increased	from	130	(64.7%)	
to	148	(75.5%),	respectively	(RR	1.17,	95%	CI	1.03–1.33)	(Table	3).
One	woman	at	baseline	and	five	during	the	intervention	months	
died	(RR	4.80,	95%	CI	0.57–40.67).	The	woman	at	baseline	died	from	
obstetric	hemorrhage.	In	the	intervention	group,	one	woman	died	from	
obstetric	hemorrhage,	and	one	had	been	referred	from	elsewhere	and	
died	on	admission.	The	other	three	women	experienced	severe	organ	
dysfunction	postpartum	in	the	study	hospital;	one	patient	had	pulmo-
nary	edema	and	hypoxia,	one	had	eclampsia	and	cerebral	edema,	and	
one	had	eclampsia	and	renal	failure.
4  | DISCUSSION
The	 present	 findings	 show	 that,	 although	 care	 remained	 substand-
ard,	 several	 improvements	 had	 occurred	 during	 the	 ninth	 to	 12th	
invention	months,	such	as	progress	in	surveillance,	a	37%	increase	in	
antihypertensive	treatment,	and	a	44%	reduction	in	risk	of	stillbirth.	
Taken	together	with	previous	studies,3,18,19	the	findings	suggest	that	
the	PartoMa	intervention	was	an	important	determinant	of	improve-
ments.	This	indicates	how	effective	locally	tailored	clinical	guidelines	
and	associated	quarterly,	low-	dose	training	can	be	in	a	weak	health-
care	system	with	critical	shortages	in	human	resources.
The	 study	 has	 both	 strengths	 and	 limitations.	 The	 low-	cost,	
pre–post	approach	had	applicable	process	and	outcome	indicators.	
The	 comparable	 background	 characteristics	 of	 women	 between	
baseline	 and	 the	 intervention	 months	 strengthened	 its	 internal	
validity.	Two	baseline	periods	would	have	enabled	potential	time-	
related	changes	 to	be	examined,	but	 the	hospital’s	poor	case	 file	
storage	prevented	this	approach.	There	were	few	contextual	con-
founders	identified,	but	the	16%	fewer	deliveries	in	the	interven-
tion	 months	 might	 have	 allowed	 better	 care.19	 Birth	 attendants	
were	not	paid	 to	attend	 the	 seminars.	Therefore,	 the	high	atten-
dance	after	working	hours	appeared	to	indicate	staff	motivation	to	
improve	care,	which	was	a	mediator	of	 improvements.19	Through	
retrieving	 all	 available	 case	 files	 from	 the	 months	 studied	 and	
reviewing	 them	manually,	 the	 number	 of	women	 in	 labor	 identi-
fied	was	2%	higher	than	if	hospital	registers	alone	had	been	used.	
This	close	approximation	in	a	low-	resource	hospital	was	a	strength.	
The	 present	 findings	 are	 further	 strengthened	 by	 triangulation	
with	similar	results	of	the	other	PartoMa	studies,	emphasizing	low	
inter-	observer	bias	 and	unambiguity	of	 indicators.3,18,19	Although	
the	 effect	 of	 the	PartoMa	 intervention	was	 explored	 in	 terms	of	
care	and	birth	outcomes,	the	available	case	file	data	did	not	enable	
analyzing	 the	 frequency	 of	 organ	 failure	 and	 neonatal	 mortality,	
the	in-	depth	quality	of	monitoring	and	treatment,	and	whether	the	
birth	 attendants’	 interactions	 with	 the	 women	 were	 respectful.	
Furthermore,	data	from	case	file	reviews	might	be	biased	owing	to	
under-	or	over-	recording.3
The	 current	 study	 shows	 that	 the	 previously	 reported	 overall	
reduction	in	stillbirths	from	59	to	39	per	1000	total	births	between	
baseline	and	the	ninth	to	12th	intervention	months19	was	also	true	
within	the	sHDP	subgroup;	stillbirths	reduced	from	20.9%	to	11.7%.	
Although	 not	 reaching	 statistical	 significance,	 the	 results	 suggest	
that	 the	 reduction	 predominantly	 occurred	 among	 intra-	hospital	
stillbirths.	Whereas	a	decrease	 in	over-	use	of	oxytocin	augmenta-
tion	seemed	to	be	a	major	contributor	among	non-	sHDP	women,19 
it	did	not	explain	the	present	reduction	in	stillbirths	observed	among	
sHDP	women.	Taken	 together	with	 our	 previous	 evaluation,19	 the	
improvements	 observed	 seem	 to	 relate	 to	 the	 three	 pages	 of	 the	
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F IGURE  3 Comparison	of	key	findings	at	baseline	(October	2014–January	2015)	and	at	9–12	months	of	the	PartoMa	study	(October	2015–
January	2016).	(A)	Stillbirths	(defined	as	fetal	death	with	weight	≥1000	g)	and	newborns	with	an	Apgar	score	of	7	or	higher.	(B)	Median	time	
between	last	recorded	fetal	heart	rate	(FHR)	or	blood	pressure	(BP)	measurement	and	delivery.	(C)	Additional	quality	indicators	of	diagnosis,	
surveillance,	and	treatment	of	women	with	severe	hypertensive	disorders	during	pregnancy	(sHDP).	Abbreviations:	CI,	confidence	interval;	IQR,	
interquartile	range;	RR,	relative	risk.	Asterisk	indicates	significant	difference.
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PartoMa	pocket	guide	 that	were	highest	 rated	among	birth	atten-
dants	 (FHR,	 labor	progress,	and	 intrapartum	HDP).18	Furthermore,	
this	 is	 consistent	with	 challenges	 identified	 in	 the	 baseline	 case–
control	study	of	stillbirth.3	It	seems	that	the	PartoMa	intervention’s	
integrated	recommendations	and	training	in	routine	and	emergency	
intrapartum	 care	 have	 helped	 to	 trigger	 quality	 improvements.	
Qualitative	implementation	research	is	warranted	to	further	identify	
organizational	and	 individual	aspects	associated	with	the	changes,	
and	with	lack	of	changes.22
Two	other	 criterion-	based	audits	 from	East	African	 referral	 hos-
pitals	 also	 included	 locally	 tailored	 guidelines	 and	 similarly	 proved	
effective	in	strengthening	care	for	women	with	HDP.	However,	their	
interventions	 were	 narrowly	 targeted	 at	 pre-	eclampsia/eclampsia	
and	 included	 additional	 structural	 changes.6,8	To	our	 knowledge,	 no	
TABLE  1 Univariable	analysis	of	the	diagnosis	and	surveillance	of	women	with	severe	hypertensive	disorders	during	childbirth,	comparison	
of	relative	risk	of	outcomes	during	the	ninth	to	12th	months	of	the	intervention	(October	1,	2015,	to	January	31,	2016)	compared	with	during	
the	baseline	period	(October	1,	2014,	to	January	31,	2015).a
Characteristic
At baseline 
(n=188)
At 9–12 intervention 
months (n=196) P value RR (95% CI)
Time	of	diagnosis	severe	hypertensive	disorder
Prenatal	care	visit 9	(4.8) 9	(4.6) 0.96	(0.39–2.36)
During	admission	assessment 82	(43.6) 110	(56.1) 1.29	(1.05–1.58)
After	admission	assessment 38	(20.2) 33	(16.8) 0.83	(0.55–1.27)
Undiagnosed 59	(31.4) 44	(22.4) 0.72	(0.51–1.00)
Physical	examination	recorded	on	diagnosis
Minimum:	headache,	epigastric	pain,	vision 25	(13.3) 41	(20.9) 1.57	(1.00–2.48)
Blood	count:	taken:	renal	and	liver	function	tests	as	minimum 23	(12.2) 61	(31.1) 2.54	(1.65–3.93)
Documentation	sheets	at	least	partially	appliedb
Women	in	first	stage	of	labor 161 155
Partograph 114	(70.8) 107	(69.0) 0.97	(0.84–1.13)
All	study	women 188 196
Specific	observation	and	treatment	sheet	for	HDP 86	(45.7) 91	(46.4) 1.01	(0.82–1.26)
Fluid	balance	sheet 14	(7.4) 31	(15.8) 2.12	(1.17–3.86)
Blood	pressure
BP	recorded	on	admission 181	(96.3) 195	(99.5) 1.03	(1.00–1.06)
Women	with	known	start	of	active	phase	of	labor 149 140
BP	recorded	at	least	once	during	active	phase	of	labor 127	(85.2) 121	(86.4) 1.01	(0.92–1.11)
All	study	women 188 196
BP	at	least	once	between	delivery	and	dischargec 126	(67.0) 151	(77.0) 1.15	(1.01–1.30)
Women	with	vaginal	delivery	and	≥1	BP	recording	during	admission 126 130
Time	from	last	BP	till	delivery,	min 162	(80–328) 129	(60–245) 0.022d
Fetal	heart	rate
Women	in	active	phase	of	labor,	no	IUFD 144 131
FHR	at	least	once	during	active	phase	of	labor 113	(78.5) 113	(86.3) 1.10	(0.99–1.23)
Women	with	recorded	FHR 140 164
Time	from	last	FHR	till	delivery,	min 150	(60–296) 90	(35–180) 0.001d
Labor	progression
Women	in	active	phase	of	labor 165 156
<5	h	between	any	two	cervical	assessmentsd 103	(62.4) 112	(71.8) 1.15	(0.99–1.34)
Abbreviations:	BP,	blood	pressure;	CI,	confidence	interval;	FHR,	fetal	heart	rate;	HDP,	hypertensive	disorders	in	pregnancy;	IUFD,	intrauterine	fetal	death;	
relative	risk.
aValues	are	given	as	number	(percentage),	absolute	number,	or	median	(interquartile	range),	unless	indicated	otherwise.
bThe	documentation	sheets	included	a	partograph	sheet	(at	least	the	first	cervical	dilatation	in	active	labor	plotted	correctly	on	the	alert	line),	a	specific	
sheet	for	HDP	(at	least	one	recorded	observation	and	treatment,	and	fluid	balance	sheet	(at	least	one	recording	of	input	and	output).
cOverall,	70/188	(37%)	at	baseline	and	82/196	(42%)	during	the	intervention	had	at	least	one	BP	recording	every	24	h	during	the	first	2	days	postpartum	
(RR	1.12,	95%	CI	0.88–1.44).
dBy	Mann-	Whitney	test	for	difference.	This	incude	the	interval	between	the	last	recording	of	cervical	dilatation	and	delivery.
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other	studies	of	broader	guidelines	have	been	shown	to	be	effective	
in	strengthening	care	and	perinatal	survival	 for	women	with	HDP	in	
low-	income	countries.
Nevertheless,	the	five	maternal	deaths	in	the	ninth	to	12th	inter-
vention	months	reflect	the	unacceptable	quality	of	care	throughout	
the	 study.	Moreover,	 the	 7%–8%	 prevalence	 of	 severe	 hyperten-
sive	disorders,	with	85%	of	affected	women	admitted	directly	from	
home	and	only	one	diagnosed	with	mild-	moderate	disease	prior	to	
this,	might	in	itself	indicate	missed	opportunities	for	early	detection	
and	treatment,	both	prenatally	and	intrapartum.	Data	from	another	
Tanzanian	 tertiary	 hospital	 reported	 an	 incidence	 of	 eclampsia	 of	
6%,6	whereas	a	facility-	based	survey	of	mild-	severe	HDP	in	multiple	
low-	 and	middle-	income	 countries	 found	 an	 overall	 prevalence	 of	
only	2.7%.2	The	high	prevalence	of	sHDP	in	the	present	study	may	
also	be	associated	with	a	high	predisposition	in	the	target	popula-
tion,	which	further	emphasizes	the	need	to	strengthen	early	detec-
tion	and	management:	19%	of	Zanzibari	women	aged	25–44	years	
are	affected	by	hypertension,23	with	the	risk	of	gestational	aggrava-
tion	and	superimposed	pre-	eclampsia.2,24
In	 quality	 improvement	 processes,	 the	 potential	 effects,	 and	
adverse	effects,	of	more	or	less	broad	focal	points	must	be	carefully	
considered.	As	 part	 of	 the	 internationally	 formulated	 obstetric	 care	
signal	 functions,	 maximizing	 magnesium	 sulfate	 coverage	 has	 been	
repeatedly	emphasized.25	At	 the	 study	hospital,	 it	was	 administered	
to	90%	of	women	with	severe	pre-	eclampsia/eclampsia	during	both	
baseline	 and	 intervention	months.	Although	 evidence	 suggests	 that	
severe	hypertension	 is	a	 similarly	 important	contributor	 to	maternal	
mortality	 in	sHDP,14	antihypertensives	are	not	 included	in	the	signal	
functions,	and	this	omission	might	have	contributed	to	more	than	half	
of	the	women	with	sHDP	at	baseline	not	receiving	antihypertensive	
treatment.	A	similar	mismatch	 in	pre-	eclampsia/eclampsia	 treatment	
was	reported	 in	Ghana,	where	health	providers	described	how	clini-
cal	guidelines	were	adhered	to	more	closely	if	they	were	given	more	
attention	and	if	local	adjustments	were	made.9	A	second	version	of	the	
brief	and	simple	PartoMa	pocket	guide	was	launched	in	2018,	with	the	
focal	point	broadened	further	by	including	additional	essential	intra-
partum	and	postpartum	care,	and	PartoMa	seminars	have	now	been	
conducted	for	nearly	4	years.21
It	remains	crucial	to	address	the	human	resources	crisis	and	sub-
standard	clinical	 competencies	among	staff,	as	well	 as	unacceptable	
shortages	 in	 supplies	 and	 space.	 Nevertheless,	 in	 the	 meantime,	
locally	tailored	clinical	guidelines	and	associated	reoccurring,	in-	house	
TABLE  2 Univariable	analysis	of	the	treatment	of	women	with	severe	hypertensive	disorders	during	childbirth,	comparison	of	relative	risk	of	
outcomes	during	the	ninth	to	12th	months	of	the	intervention	(October	1,	2015,	to	January	31,	2016)	compared	with	during	the	baseline	
period	(October	1,	2014,	to	January	31,	2015).a
Characteristic
At baseline 
(n=188)
At 9–12 intervention 
months (n=196) P value RR (95% CI)
Antihypertensive	treatment
All	women	with	severe	hypertensionb 184 193
Hydralazine	or	nifedipine	administered 86	(46.7) 124	(64.2) 1.37	(1.14–1.66)
Anticonvulsant	treatment
Women	with	urine	protein	≥2	or	eclampsiac 121 144
MgSO4	treatment	initiated 110	(90.9) 127	(88.2) 0.97	(0.89–1.05)
Women	receiving	MgSO4 110 127
Patellar	reflexes	and	respiratory	rate	at	least	once 20	(18.2) 44	(34.6) 1.91	(1.20–3.03)
Labor	progression
All	women	with	the	required	date	and	time	recorded: 173 189
Time	from	inclusion	criteria	recorded	till	delivery,	min 390	(161–790) 457	(225–745) 0.356d
All	study	women 188 196
Partograph	action	line	crossed	(prolonged	first	stage) 22	(11.7) 22	(11.2) 0.96	(0.55–1.67)
Induction	of	labore 48	(25.5) 75	(38.3) 1.50	(1.11–2.03)
Oxytocin	for	augmentation	in	active	phase	of	laborf 45	(23.9) 36	(18.4) 0.77	(0.52–1.13)
Abbreviations:	CI,	confidence	interval;	MgSO4,	magnesium	sulfate;	RR,	relative	risk.
aValues	are	given	as	absolute	number,	number	(percentage),	or	median	(interquartile	range),	unless	indicated	otherwise.
bDiagnostic	criteria	for	severe	hypertension	applied:	systolic	BP	≥160	mm	Hg	and/or	diastolic	BP	≥110	mm	Hg.
cDiagnostic	criteria	for	severe	pre-	eclampsia/eclampsia	applied:	severe	hypertension	on	at	least	one	reading	and	urine	protein	≥2,	or	eclampsia/convulsions	
described	(owing	to	poor	data	quality,	women	without	severe	hypertension	or	eclampsia,	but	fulfilling	the	WHO	criteria	of	severe	pre-	eclampsia	due	to	
symptoms	of	organ	failure	could	not	be	identified).	For	an	additional	28/188	(15%)	women	at	baseline	and	12/193	(6%)	during	the	intervention,	urine	
dipstick	was	not	performed.
dMann-	Whitney	test	for	difference.
eOne	woman	was	induced	by	balloon	catheter;	all	others	were	induced	by	misoprostol	with	or	without	subsequent	oxytocin.
fWomen	were	excluded	if	induced.	For	11/45	(24%)	and	7/36	(19%),	respectively,	membranes	were	still	intact	when	starting	oxytocin	augmentation	(RR	
0.80,	95%	CI	0.34–1.84).
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training,	which	takes	account	of	the	current	resource	constraints,	are	
warranted	in	assisting	work-	overloaded	birth	attendants	in	improving	
care.	Achievable	guidance	is	a	basic	right	for	birth	attendants	holding	
the	lives	of	others	in	their	hands.
AUTHOR CONTRIBUTIONS
NM	 contributed	 to	 the	 design	 of	 the	 study,	 data	 collection	 and	
analysis,	 data	 interpretation,	 and	 writing	 the	 manuscript.	 CBA	
contributed	 to	 the	design	of	 the	 study,	data	 collection	and	analy-
sis,	and	revising	the	manuscript.	NH	contributed	to	data	collection	
and	analysis,	and	 revising	 the	manuscript.	TM	contributed	 to	data	
interpretation	and	revising	the	manuscript.	ICB	and	JvR	contributed	
to	the	design	of	the	study	and	revising	the	manuscript.	All	authors	
approved	the	final	manuscript	and	agreed	to	be	accountable	for	all	
aspects	of	the	work.
ACKNOWLEDGMENTS
The	 PartoMa	 study	 is	 financed	 by	 grants	 from	 the	 Lundbeck	
Foundation	(R164-	2013-	16038),	the	Laerdal	Foundation	(40108),	the	
Augustinus	 Foundation	 (14-	1059),	 and	 University	 of	 Copenhagen.	
The	funding	bodies	have	no	role	in	the	design,	implementation,	inter-
pretation,	or	reporting	of	the	study.
CONFLICTS OF INTEREST
The	authors	have	no	conflicts	of	interest.
REFERENCES
	 1.	 Khan	 KS,	Wojdyla	 D,	 Say	 L,	 Gülmezoglu	 AM,	 Van	 Look	 PF.	WHO	
analysis	 of	 causes	 of	 maternal	 death:	 A	 systematic	 review.	 Lancet. 
2006;367:1066–1074.
TABLE 3 Birth	outcomes	among	women	with	severe	hypertensive	disorders,	comparison	of	relative	risk	of	outcomes	during	the	ninth	to	12th	
months	of	the	intervention	(October	1,	2015,	to	January	31,	2016)	compared	with	during	the	baseline	period	(October	1,	2014,	to	January	31,	2015).a
Outcome Baseline At 9–12 intervention months RR (95% CI)
Maternal	outcomes 188 196
Maternal	death 1	(0.5) 5	(2.6) 4.80	(0.57–40.67)
Day	of	discharge	postpartumb
Delivery day 65	(34.6) 66	(33.7) 0.97	(0.74–1.29)
1–2	d	postpartum 35	(18.6) 64	(32.7) 1.75	(1.22–2.51)
≥3	d	postpartum 88	(46.8) 67	(34.2) 0.73	(0.57–0.93)
Neonatal	outcomes 203 206
Mode	of	delivery
Spontaneous	vaginal 133	(65.5) 130	(63.1) 0.96	(0.83–1.11)
Vaginal	breech 10	(4.9) 6	(2.9) 0.59	(0.22–1.60)
Vacuum	extraction 0 4	(1.9)
Cesarean 58	(28.6) 63	(30.6) 1.07	(0.79–1.44)
Unknown 2	(1.0) 3	(1.5) 1.48	(0.25–8.75)
Neonatal	outcomes	for	those	with	birthweight	≥1000	gc 201 196
Apgar	score
≥7 130	(64.7) 148	(75.5) 1.17	(1.03–1.33)
6 5	(2.5) 7	(3.6) 1.44	(0.46–4.45)
1–5 19	(9.5) 12	(6.1) 0.65	(0.32–1.30)
0	(stillbirths) 42	(20.9) 23	(11.7) 0.56	(0.35–0.90)
Information	missing 5	(3.0) 6	(2.9) 1.23	(0.38–3.97)
Stillbirths,	time	of	death
Pre-	hospital	(fetal	death	diagnosed	on	admission) 18	(9.0) 14	(7.1) 0.80	(0.41–1.56)
Intra-	hospital	(positive	FHR	on	admission) 18	(9.0) 9	(4.6) 0.51	(0.24–1.11)
Time	unknown	(no	documented	FHR	during	admission) 6	(3.0) 0
Abbreviations:	CI,	confidence	interval;	FHR,	fetal	heart	rate;	RR,	relative	risk.
aValues	are	given	as	absolute	number	or	number	(percentage),	unless	indicated	otherwise.
bThe	last	recording	in	the	file	was	treated	as	the	last	day	of	stay.
cOf	all	neonates,	2/203	(1%)	at	baseline	and	10/206	(4.9%)	during	the	intervention	had	birthweight	<1000	g	approximate	pregnancy	duration	<28	wk).	At	
the	 study	hospital,	 stillbirths	 at	 <28	weeks	 are	 classified	 as	 late	 spontaneous	 abortions.	Although	 there	might	 be	 a	 risk	of	mis-	categorizing	 stillbirths	
affected	by	severe	intrauterine	growth	restriction,	those	stillbirths	were	excluded	from	the	perinatal	outcome	data.
36  |     Maaløe eT al.
	 2.	 Abalos	 E,	 Cuesta	 C,	 Carroli	 G,	 et	 al.	 Pre-	eclampsia,	 eclampsia	 and	
adverse	maternal	 and	 perinatal	 outcomes:	A	 secondary	 analysis	 of	
the	World	Health	Organization	Multicountry	Survey	on	Maternal	and	
Newborn	Health.	BJOG. 2014;121:14–24.
	 3.	 Maaløe	N,	Housseine	N,	Bygbjerg	IC,	et	al.	Stillbirths	and	quality	of	
care	during	labour	at	the	low	resource	referral	hospital	of	Zanzibar:	A	
case-	control	study.	BMC Pregnancy Childbirth. 2016;16:351.
	 4.	 Nelissen	 EJT,	Mduma	 E,	 Ersdal	 HL,	 Evjen-Olsen	 B,	 van	 Roosmalen	
JJM,	 Stekelenburg	 J.	 Maternal	 near	 miss	 and	 mortality	 in	 a	 rural	
referral	hospital	 in	northern	Tanzania:	A	cross-	sectional	study.	BMC 
Pregnancy Childbirth. 2013;13:141.
	 5.	 Lumala	 A,	 Sekweyama	 P,	 Abaasa	 A,	 Lwanga	 H,	 Byaruhanga	 R.	
Assessment	 of	 quality	 of	 care	 among	 in-	patients	 with	 postpartum	
haemorrhage	and	severe	pre-	eclampsia	at	st.	Francis	hospital	nsam-
bya:	A	criteria-	based	audit.	BMC Pregnancy Childbirth. 2017;17:29.
	 6.	 Kidanto	HL,	Wangwe	P,	Kilewo	CD,	Nystrom	L,	Lindmark	G.	Improved	
quality	of	management	of	eclampsia	patients	through	criteria	based	
audit	 at	 Muhimbili	 National	 Hospital,	 Dar	 es	 Salaam,	 Tanzania.	
Bridging	the	quality	gap.	BMC Pregnancy Childbirth. 2012;12:134.
	 7.	 Herklots	T,	van	Acht	L,	Meguid	T,	Franx	A,	Jacod	B.	Severe	maternal	
morbidity	in	Zanzibar’s	referral	hospital:	Measuring	the	impact	of	in-	
hospital	care.	PLoS ONE. 2017;12:e0181470.
	 8.	 Weeks	AD,	Alia	G,	Ononge	S,	Otolorin	EO,	Mirembe	FM.	A	criteria-	
based	audit	of	the	management	of	severe	pre-	eclampsia	in	Kampala,	
Uganda.	Int J Gynecol Obstet. 2005;91:292–297.
	 9.	 Browne	JL,	van	Nievelt	 SW,	 Srofenyoh	EK,	Grobbee	DE,	Klipstein-
Grobusch	K.	Criteria-	based	audit	 of	 quality	of	 care	 to	women	with	
severe	 pre-	eclampsia	 and	 eclampsia	 in	 a	 referral	 hospital	 in	Accra,	
Ghana. PLoS ONE. 2015;10:e0125749.
	10.	 Oladapo	O,	Adetoro	O,	Ekele	B,	Chama	C,	Etuk	S,	Aboyeji	A,	et	al.	
When	getting	there	is	not	enough:	A	nationwide	cross-	sectional	study	
of	998	maternal	deaths	and	1451	near-	misses	in	public	tertiary	hospi-
tals	in	a	low-	income	country.	BJOG. 2015;123:928–938.
	11.	 Meguid	T.	(Re)Humanising	Health	Care	–	placing	dignity	and	agency	of	
the	patient	at	the	centre.	Nord J Hum Rights Routledge. 2016;34:60–64.
	12.	 Chou	D,	Daelmans	B,	Jolivet	RR,	Kinney	M,	Say	L;	Every	Newborn	
Action	 Plan	 (ENAP)	 and	 Ending	 Preventable	 Maternal	 Mortality	
(EPMM)	working	groups.	Ending	preventable	maternal	and	newborn	
mortality	and	stillbirths.	BMJ. 2015;351:h4255.
	13.	 World	Health	Organization.	WHO recommendations for Prevention and 
treatment of pre-eclampsia and eclampsia.	Geneva,	Switzerland:	World	
Health	Organization;	2011.
	14.	 von	Dadelszen	P,	Firoz	T,	Donnay	F,	 et	 al.	Preeclampsia	 in	 low	and	
middle	 income	 countries-	health	 services	 lessons	 learned	 from	 the	
PRE-	EMPT	 (PRE-	eclampsia-	eclampsia	 monitoring,	 prevention	 and	
treatment)	project.	J Obstet Gynaecol Canada. 2012;34:917–926.
	15.	 Miller	S,	Abalos	E,	Chamillard	M,	et	al.	Beyond	too	little,	too	late	and	
too	much,	too	soon:	A	pathway	towards	evidence-	based,	respectful	
maternity	care	worldwide.	Lancet. 2016;388:2176–2192.
	16.	 Ameh	CA,	Ekechi	CI,	Tukur	J.	Monitoring	severe	pre-	eclampsia	and	
eclampsia	 treatment	 in	 resource	poor	countries:	Skilled	birth	atten-
dant	perception	of	a	new	treatment	and	monitoring	chart	 (LIVKAN	
chart).	Matern Child Health J. 2012;16:941–946.
	17.	 Ministry	 of	 Health	 and	 Social	Welfare	 (Dar	 es	 Salaam)	 &	 Ministry	
of	Health	 (Zanzibar).	Tanzania	Service	Provision	Assessment	Survey	
2014–2015.	Dar	es	Salaam;	2016.
	18.	 Maaløe	 N,	 Housseine	 N,	 van	 Roosmalen	 J,	 et	 al.	 Labour	 manage-
ment	 guidelines	 for	 a	Tanzanian	 referral	 hospital:	The	 participatory	
development	 process	 and	 birth	 attendants’	 perceptions.	 BMC 
Pregnancy Childbirth. 2017;17:175.
	19.	 Maaløe	 N,	 Housseine	 N,	Meguid	 T,	 et	 al.	 Effect	 of	 locally-	tailored	
labour	management	 guidelines	 on	 intrahospital	 stillbirths	 and	 birth	
asphyxia	 at	 the	 referral	 hospital	 of	 Zanzibar:	A	 quasi-	experimental	
pre-	post-	study	(The	PartoMa	study).	BJOG. 2017;125:235–245.
	20.	 Kwast	 BE,	 Lennox	 CE,	 Farley	 TMM;	 World	 Health	 Organization	
partograph	 in	 management	 of	 labour.	 World	 Health	 Organization	
Maternal	 Health	 and	 Safe	 Motherhood	 Programme.	 Lancet. 
1994;343:1399–1404.
	21.	 University	of	Copenhagen.	The	PartoMa	Study	–	 for	 saving	 lives	at	
birth	[Internet].	https://publichealth.ku.dk/partoma.	Accessed	June	1,	
2018.
	22.	 Bonell	C,	Fletcher	A,	Morton	M,	Lorenc	T,	Moore	L.	Realist	randomised	
controlled	trials:	A	new	approach	to	evaluating	complex	public	health	
interventions.	Soc Sci Med. 2012;75:2299–2306.
	23.	 Jorgensen	 J.	 NCD	 Survey	 Report:	Main	 findings	 from	 the	National	
Non-Communicable	Disease	Risk	Factor	Survey	2011.	Zanzibar	City;	
2012.
	24.	 Bramham	K,	Parnell	B,	Nelson-Piercy	C,	Seed	PT,	Poston	L,	Chappell	
LC.	 Chronic	 hypertension	 and	 pregnancy	 outcomes:	 Systematic	
review	and	meta-	analysis.	BMJ. 2014;348:g2301.
	25.	 Maine	 D.	 World	 Health	 Organization,	 Reproductive	 Health	 and	
Research.	Monitoring emergency obstetric care : A handbook.	Geneva,	
Switzerland:	 Dept.	 of	 Reproductive	 Health	 and	 Research,	 World	
Health	Organization;	2009.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.
File S1.	PartoMa	Pocket	Guide	version	1	applied	in	the	present	study.
Figure S1.	 Indicators	 analyzed	 to	 assess	 intrapartum	quality	 of	 care	
and	 birth	 outcomes	 among	women	with	 severe	 hypertensive	 disor-
ders	of	pregnancy	 (sHDP).	The	 indicators	are	unambiguous	research	
criteria	 that	 are	 sensitive	 in	 monitoring	 care	 progress	 at	 the	 low-	
resource	study	site	and	can	be	retrieved	from	the	case	files.	They	do	
not	 represent	 acceptable	 quality	 of	 care.	The	 following	documenta-
tion	sheets	(asterisk)	were	used:	a	partograph	sheet	(at	least	the	first	
cervical	dilatation	in	active	labor	plotted	correctly	on	the	alert	line),	a	
specific	sheet	for	HDP	(at	least	one	recorded	observation),	and	a	fluid	
balance	sheet	(minimum	of	one	recording	of	input	and	output).	Severe	
hypertension	(double	asterisk)	was	defined	as	systolic	blood	pressure	
(BP)	160	mm	Hg	or	higher	and/or	diastolic	BP	110	mm	Hg	or	higher.	
Severe	pre-	eclampsia	(triple	asterisk)	was	defined	as	severe	hyperten-
sion	on	at	least	one	reading	and	proteinuria	of	at	least	2+,	or	recorded	
eclampsia/convulsions	 before	 or	 during	 admission.	 Abbreviations:	
FHR,	fetal	heart	rate;	IUFD,	intrauterine	fetal	death.
Table S1.	Background	characteristics	of	women	 included	at	baseline	
and	at	9–12	mo	of	the	PartoMa	intervention.
